Seres Therapeutics (MCRB) Current Deferred Revenue (2016 - 2024)
Seres Therapeutics (MCRB) posted Current Deferred Revenue of $7.9 million for Q2 2024, down 2.31% sequentially from $8.1 million in Q1 2024, and up 181.22% YoY from $2.8 million in Q3 2023.
Seres Therapeutics (MCRB) Current Deferred Revenue (2016 - 2024) Analysis & Trends
Seres Therapeutics has reported Current Deferred Revenue for 9 years, with the latest figure at $7.9 million in Q2 2024.
- Quarterly Current Deferred Revenue rose 181.22% year-over-year to $7.9 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $7.9 million (up 181.22% YoY) and the FY2023 annual result came in at $7.7 million, up 81.5% from the prior year.
- Current Deferred Revenue fell to $7.9 million in Q2 2024 per MCRB's latest filing, from $8.1 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $22.6 million in Q4 2020 and troughed at $364000.0 in Q3 2023.
- A 5-year average of $11.0 million and a median of $8.5 million in 2020 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue plunged 92.52% in 2023, then surged 241.29% in 2024.
- Over 5 years, Current Deferred Revenue stood at $22.6 million in 2020, then fell by 25.59% to $16.8 million in 2021, then tumbled by 74.68% to $4.3 million in 2022, then soared by 81.5% to $7.7 million in 2023, then climbed by 2.48% to $7.9 million in 2024.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $7.9 million, $8.1 million, and $7.7 million for Q2 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 7.92 Mn |
| Mar 31, 2024 | 8.11 Mn |
| Dec 31, 2023 | 7.73 Mn |
| Sep 30, 2023 | 364,000.00 |
| Jun 30, 2023 | 2.82 Mn |
| Mar 31, 2023 | 2.38 Mn |
| Dec 31, 2022 | 4.26 Mn |
| Sep 30, 2022 | 4.87 Mn |
| Jun 30, 2022 | 11.10 Mn |
| Mar 31, 2022 | 20.44 Mn |
| Dec 31, 2021 | 16.82 Mn |
| Sep 30, 2021 | 21.62 Mn |
| Jun 30, 2021 | 19.83 Mn |
| Mar 31, 2021 | 21.24 Mn |
| Dec 31, 2020 | 22.60 Mn |
| Sep 30, 2020 | 8.48 Mn |
| Jun 30, 2020 | 8.48 Mn |
| Mar 31, 2020 | 8.50 Mn |
| Dec 31, 2019 | 9.67 Mn |
| Sep 30, 2019 | 4.20 Mn |